Tirilizumab mostly refers to tirilizumab injection, which is not currently approved for use in nasopharyngeal carcinoma, but there are study data suggesting that some patients may benefit. Tirilizumab injection is mainly applied to relapsed or refractory classical Hodgkin’s lymphoma that has been treated with at least second-line systemic chemotherapy, as well as locally advanced or metastatic uroepithelial carcinoma, locally advanced or metastatic squamous non-small-cell lung cancer, etc. This drug is currently in the stage of nasopharyngeal carcinoma clinical trials, and the relevant data of the study show that some patients can be benefited. Nasopharyngeal cancer is a kind of malignant tumor occurring in the mucosal epithelium of nasopharynx, and this disease is very sensitive to radiotherapy. Early stage nasopharyngeal cancer may be cured by pure radiotherapy, and other treatments such as chemotherapy are usually needed for middle and late stage. Due to the difference in the severity of disease, clinical staging, individual physique and other factors, the specific treatment plan may be different, so please follow the guidance of professional doctors for specific conditions.